Organoid Culture Seed Expansion Patents: Leaders & Trends 2026
- Concentrated at the top. The five most active filers together hold 41.1% of all 850 records in scope, and the ten most active hold 54.7%.
- Filing has cooled from its peak. After peaking at 80 filings in 2021, annual filings fell to 35 by 2024 — a 56% drop over that three-year span.
- Claims cluster in one class. 95.5% of records carry a C12N classification, with medicinal preparations (A61K, 29.5%) and testing methods (G01N, 24.0%) as the next densest layers.
Filing growth compares 2021 (80 records) with 2024 (35) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 850 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent activity at the intersection of organoid and organotypic culture methods and the operational parameters that govern seed expansion — seeding density, passage number, viability thresholds, doubling time, inoculum trains and culture transitions. The scope spans 850 published records filed or published between 2015 and mid-2026, classified under core cell-culture IPC codes (C12N5/071, C12N5/00, C12M3/00).
The records span jurisdictions from the United States and Europe through WIPO's PCT route to Australia, Israel and Canada, reflecting a field where methods first proven in academic and biotech labs are pursued for broad multi-territory protection before commercial cell-therapy or drug-screening products reach market.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 850 records: how filing volume has moved year over year, and which IPC subclasses carry the claim density within those filings.
Filing trend, 2017–2026
Annual filings rose to a peak of 80 in 2021, then declined to 35 by 2024 — a 56% fall over that three-year span. 2025 and 2026 figures are still incomplete because publication typically lags filing by around 18 months, so the most recent years should not yet be read as a continued decline.
IPC subclass composition
Almost every record in scope (95.5%) touches C12N — microorganisms and genetic engineering — confirming this as the structural core of the field. Medicinal preparations (A61K, 29.5%) and material testing (G01N, 24.0%) are the next largest layers, followed by sterilising methods, bioreactor apparatus, enzyme/DNA measurement, therapeutic activity and peptide chemistry. Because records can carry several classes, these shares sum to well over 100% of the 850-record total.
Shares are the percentage of the 850 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Organoid Culture Seed Expansion with Eureka
This page is one run against one query. Ask Eureka your own question about organoid culture seed expansion and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
EP2718422A2 — Culture media for stem cells
Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine.Filed by Koninklijke Nederlandse Akademie van Wetenschappen (KNAW), published 2014-04-16.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1998008934A1 | Serum-free mammalian cell culture medium, and uses thereof | 332 |
| 2 | WO1998015614A1 | Animal cell culture media comprising plant-derived nutrients | 300 |
| 3 | WO2012168930A2 | Culture media for stem cells | 246 |
| 4 | US20080070303A1 | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained ther… | 201 |
| 5 | US20100184033A1 | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained ther… | 190 |
| 6 | WO2001021767A2 | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof | 149 |
| 7 | US20140243227A1 | Culture media for stem cells | 140 |
| 8 | US20060148074A1 | Serum-free mammalian cell culture medium, and uses thereof | 124 |
| 9 | US6103529A | Animal cell culture media comprising peptides derived from rice | 122 |
| 10 | WO1999057246A1 | Animal cell culture media comprising non-animal or plant-derived nutrients | 112 |
Citation counts accumulate over time, so older culture-media filings dominate this list; treat them as markers of influence on later work rather than as the field's current centre of gravity.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Reading concentration, technology composition and citation patterns together points to where claim space is occupied and where it is not.
A short list of repeat filers sets the terms
The five most active assignees account for 41.1% of all 850 records, rising to 54.7% across the ten most active. That leaves a long tail of single- or few-filing entrants working around a small set of established method claims.
Volume has pulled back from its 2021 peak
Filings rose to 80 in 2021 before falling to 35 by 2024, a 56% decline over three years. Because publication lags filing by roughly 18 months, 2025–2026 figures are still incomplete and should not be read as confirming further decline.
One class anchors nearly the whole field
C12N classifications appear on 95.5% of records, with A61K (29.5%) and G01N (24.0%) as the next-largest overlapping layers. Bioreactor apparatus (C12M, 13.9%) and enzyme/DNA measurement (C12Q, 9.6%) are present but thinner, suggesting less-crowded claim territory around process hardware and assay integration.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organoid culture seed expansion, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| The University of North Carolina at Chapel Hill | University of Rome | 9 |
| Children's Hospital Medical Center (Cincinnati) | Japan Science and Technology Agency (JST) | 7 |
| Xilis, Inc. | DELUBAC DANIEL | 7 |
| Xilis, Inc. | Duke University | 6 |
| The University of North Carolina at Chapel Hill | University of Washington | 5 |
| Xilis, Inc. | NELSON DANIEL | 5 |
| Xilis, Inc. | FREED DANIEL | 5 |
| Xilis, Inc. | CALAWAY JOHN | 5 |
Ten identified co-assignee pairs exist in this landscape, the strongest linking two university groups on nine shared records — a sign that some seed-expansion method claims are still being developed through academic partnerships rather than filed solo.
Who is filing, and where activity is slowing
Recent-year momentum figures show that even among the more active assignees, filing activity in the latest tracked year has dropped sharply or stopped, consistent with the field's post-2021 pullback in overall volume.
One filer sits well ahead of fifth place
The leading assignee holds 133 records against 30 at fifth place and 20 at tenth — a steep drop-off that marks this as a field with one dominant filer rather than a tightly bunched top group.
Recent-year activity has gone quiet even among leaders
Multiple previously active assignees show zero filings in the latest tracked year, including entities that had built meaningful portfolios earlier in the period. This tracks with the broader post-2021 volume pullback rather than signalling exit from the field.
A handful of filers still co-develop
Ten co-assignee pairings appear in the dataset, the strongest spanning nine shared records between two university-affiliated groups. This is a modest but persistent pattern of joint filing rather than a dominant strategy.
| Assignee | Recent year | YoY |
|---|---|---|
| Royal Netherlands Academy of Arts and Sciences (KNAW) | 1 | -67% |
| Children's Hospital Medical Center (Cincinnati) | 0 | -100% |
| Life Technologies Corporation | 0 | -100% |
| Emulate, Inc. | 0 | — |
| Stratatech Corporation | 0 | — |
| The University of North Carolina at Chapel Hill | 0 | — |
| Invitrogen Corporation | 0 | — |
| President and Fellows of Harvard College | 0 | — |
Where to take this analysis
The dataset points to a field with an occupied core and a thinning edge. The next steps depend on whether you are clearing a specific method or scouting for open claim space.
Map claims against the C12N core
Since 95.5% of records touch C12N, any new seed-expansion method should be checked against this class first before assuming an opening elsewhere.
Explore the IPC landscape in EurekaWatch the leader's next moves
With one assignee holding 133 records against a fifth-place count of 30, tracking that portfolio's recent filings is more informative than watching the field average.
Set up assignee tracking in EurekaTest the under-claimed branches
Bioreactor culture-transition sensing and inoculum-train automation show thinner filing density than the medicinal-preparation core, worth a freedom-to-operate check before committing R&D.
Run a white space search in EurekaCommon questions about this landscape
One assignee leads with 133 records, well ahead of the fifth-ranked filer at 30 and the tenth-ranked at 20. The top five filers combined account for 41.1% of all 850 records in scope, and the top ten account for 54.7%. This means the field has a genuine leader rather than a tightly bunched group at the top, with a long tail of single- or few-filing entrants beneath the ranked group.
Filings rose to a peak of 80 in 2021, then fell to 35 by 2024 — a 56% decline over that three-year span. However, publication typically lags filing by around 18 months, so 2025 and 2026 figures in the underlying data are still incomplete. It is accurate to say the field has pulled back from its 2021 peak, but not yet accurate to call the most recent one or two years a continued decline.
C12N, covering microorganisms and genetic engineering, appears on 95.5% of the 850 records in scope and is the structural core of this landscape. Medicinal preparations (A61K, 29.5% of records) and material testing methods (G01N, 24.0%) are the next-largest overlapping classes. Bioreactor apparatus (C12M) and enzyme/DNA measurement (C12Q) appear on a smaller share of records, around 13.9% and 9.6% respectively, indicating comparatively less-crowded claim territory around culture hardware and assay integration.
EP2718422A2, filed by Koninklijke Nederlandse Akademie van Wetenschappen (KNAW) and published in 2014, claims culture media and methods for expanding and differentiating stem cell populations to obtain organoids, along with the resulting cell populations and organoids and their use in drug screening, toxicity assays and regenerative medicine. It sits within the same IPC territory as the majority of this landscape's records. Anyone developing a seeding or expansion medium for organoid work should review its specific claim scope before assuming freedom to operate.
The technology composition data shows a steep drop-off from the C12N core (95.5% of records) down to bioreactor apparatus and enzyme/DNA measurement classes, both under 15% of records. Sub-areas such as automated inoculum-train scale-up, passage-number-linked viability scoring and bioreactor culture-transition sensing show thinner filing density than the medicinal-preparation and testing core. These are reasonable starting points for a freedom-to-operate check, though thin filing density should be confirmed against a full search rather than assumed from composition shares alone.
Research Organoid Culture Seed Expansion in depth with Eureka
Go past this page: query the whole organoid culture seed expansion corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.